Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Big Hit Entertainment, the Netmarble-backed talent management agency and record company, priced its initial public offering at the top of its range.

University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.

MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.

Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.